Silverberg Bernstein Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.54M Sell
104,363
-57
-0.1% -$1.9K 1.35% 19
2026
Q1
$3.15M Buy
104,420
+9,103
+10% +$293K 1.73% 17
2025
Q4
$2.97M Buy
95,317
+4,000
+4% +$98.5K 1.72% 18
2025
Q3
$1.84M Buy
91,317
+6,000
+7% +$105K 1.12% 26
2025
Q2
$1.43M Buy
85,317
+13,157
+18% +$212K 0.98% 31
2025
Q1
$1.11M Buy
72,160
+3,720
+5% +$66.5K 1.03% 28
2024
Q4
$1.51M Sell
68,440
-600
-0.9% -$10.9K 1.33% 19
2024
Q3
$1.24M Buy
69,040
+1,800
+3% +$31.5K 1.14% 22
2024
Q2
$1.09M Hold
67,240
– – 1.06% 26
2024
Q1
$949K Hold
67,240
– – 0.93% 29
2023
Q4
$702K Buy
+67,240
New +$628K 0.67% 32

Other funds holding TEVA

Silverberg Bernstein Capital Management's TEVA Position: Q2 2026 in Review

Silverberg Bernstein Capital Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 0.05% in Q2 2026, selling an estimated $1.9K and leaving 104,363 shares worth $3.54M. The position accounts for 1.35% of the portfolio, ranked #19.

Silverberg Bernstein Capital Management first reported a position in TEVA in Q4 2023 and has held it in 11 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Silverberg Bernstein Capital Management held 104,363 shares of Teva Pharmaceutical Industries Limited worth $3.54M as of Q2 2026.
  • Silverberg Bernstein Capital Management sold 57 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $1.9K.
  • Teva Pharmaceutical Industries Limited made up 1.35% of Silverberg Bernstein Capital Management's portfolio in Q2 2026, its #19 holding.
  • Silverberg Bernstein Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2023 and has held it in 11 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q2 2026, filed 7 Jul 2026.